Compare Amylx Pharmaceuticals Inc (AMLX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Energy Select Sector SPDR Fund — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Energy Select Sector SPDR Fund trades at $55.69. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| AMLX | XLE | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | — |
52-Week High | $18.70 | $62.57 |
52-Week Low | $7.64 | $42.12 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
XLE, the Energy Select Sector SPDR ETF, trades at $55.08, up 0.49% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF has gained 21% year-to-date as of July 2, 2026 (ETF Trends), benefiting from oil price volatility and geopolitical tensions. Recent news highlights sector strength, though oil price fluctuations and concentration in 21 holdings pose considerations.
Outlook remains supported by energy demand and disciplined capital expenditure, but risks include oil price sensitivity and political pressure. Analyst sentiment is mixed, with technical strength offsetting fundamental valuation gaps. The dividend yield and expense ratio advantages are positive, yet investors face volatility from crude market dynamics and election-related policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
